ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Market Cap	61.54M
Revenue (ttm)	9.22M
Net Income (ttm)	-34.63M
Shares Out	2.66M
EPS (ttm)	-17.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,918
Average Volume	38,172
Open	22.75
Previous Close	23.00
Day's Range	21.20 - 23.25
52-Week Range	15.74 - 66.56
Beta	1.99
RSI	57.34
Earnings Date	May 1, 2025

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 18
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EXPRS2

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.